VYGLEA — 2266135
Application number
2266135
Registration number
TMA1364990
Type(s)
Standard Characters
Category
Trademark
CIPO Status
REGISTERED
TM5 status
LIVE/REGISTRATION/Issued
and Active
The trademark application has been registered with the Office.
Filed
2023-06-27
Registered
2025-12-05
Registration Expiry Date
2035-12-05
Registered Owner
Biohaven Therapeutics Ltd.
Road Town
Ritter House, P.O. Box 173
Tortola, VG1110
VIRGIN ISLANDS (BRITISH)
Agent
SMART & BIGGAR LP
Scotia Plaza, 40 King Street West
40th Floor
Toronto
ONTARIO M5H3Y2
Documents
Index headings
- VYGLEA
Goods (Nice class & Statement)
- 5
- (1) Medicated and pharmaceutical preparations, both prescription and over-the-counter, for the treatment of central nervous system disorders, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, epilepsy, neurologic illnesses in the nature of brain injury, spinal cord injury, seizure disorders, and psychiatric illnesses in the nature of anxiety disorder, depression, Bipolar Disorder, Post-Traumatic Stress Disorder (PTSD), Schizophrenia, Eating Disorders, disruptive behaviour, dissocial disorders, Neurodevelopmental disorders, for the treatment of brain ischemia, post-stroke recovery, severe intracranial atherosclerosis, carotid endarterectomy, cardiac bypass, cerebral vasculitis, reversible cerebral vasoconstriction syndrome, for the treatment of neurodegenerative diseases, in the nature of Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Huntington's disease, Lewy body dementia, frontotemporal dementia, vascular dementia, Parkinson's disease, cognitive impairment of aging, progressive Multiple Sclerosis, for the treatment of pain, in the nature of opioid sparing analgesia, chronic neuropathic pain, peripheral neuropathy, low back pain in the nature of failed back surgery syndrome, radiculopathy in the nature of sciatica, diabetic peripheral neuropathy, post-herpetic neuralgia, medication induced neuropathies, complex regional pain syndrome, fibromyalgia, chronic post-operative pain, cluster thoracotomy, phantom limb, stump neuroma, for the treatments of degenerative diseases, in the nature of breath holding in Rett syndrome, dystonias, dysphagia, gait abnormalities, bulbar function in ALS, pseudobulbar affect, levodopa-induced dyskinesias in Parkinson's disease, agitation in AD, disinhibition in dementia, for the treatment of neuropsychiatric disorders, in the nature of treatment resistant depression, Post Traumatic Stress Disorder (PTSD) in the nature of hyperarousal, substance abuse disorders, addiction disorders, Obsessive Compulsive Disorder (OCD), hoarding, trichotillomania, eating disorders, Generalized Anxiety Disorder (GAD), adjustment disorders, panic disorder, major depressive episode, bipolar disorder in the nature of manic and depressive episodes, dysthymia, cyclothymia, psychotic disorders, schizophrenia, for the treatment of cancer, for the treatment of cerebellar disorders, in the nature of spinocerebellar ataxia, Friedriech's ataxia, multisystem atrophy, essential tremor, for the treatment of brain and cord injuries, in the nature of post-intracranial hemorrhage recovery, traumatic brain injury, spinal cord injury, for the treatment of optic and retinal neuropathies, in the nature of glaucoma, diabetic retinopathy, ischemic optic and retinal neuropathies, for the treatment of headache and facial pain, in the nature of headache, migraine, chronic daily headache, cluster headache, trigeminal neuralgia, for the treatment of hearing disorders, tinnitus, delirium, sleep disorders, parasomnias, learning disorders, Attention Deficit Disorder (ADD), Pervasive Developmental Disorders (PDD), Asperger's syndrome, autism, menopausal hot flashes.
Action History
| Action | Action date | Due date | Comments |
|---|---|---|---|
| Filed | 2023-06-27 | ||
| Created | 2023-06-27 | ||
| Formalized | 2023-06-27 | ||
| Pre-Assessment Letter Sent | 2023-07-13 | Goods or Services Not Acceptable | |
| Agent Name Changed | 2024-02-28 | ||
| Agent Name Changed | 2024-02-28 | ||
| Search Recorded | 2024-11-12 | ||
| Examiner's First Report | 2024-11-12 | 2025-05-12 | |
| Approval Notice Sent | 2025-07-09 | APPROVED BY PROGRAM EX200M1 | |
| Approved | 2025-07-09 | APPROVED BY PROGRAM EX200M1 | |
| Advertised | 2025-09-17 | Vol.72 Issue 3699 | |
| Registration Pending | 2025-12-05 | ||
| Registered | 2025-12-05 | 2035-12-05 | |
| Agent Changed | 2026-04-21 | Transferred From: 5784 To: 59 |